Vinpocetine Covex 5 mg improves cerebral blood flow, decreases cerebral vascular oxygen and glucose utilization. Vinpocetine Covex 5 mg inhibits phosphodiesterase activity, prevent platelet aggregation and adenosine intake by erythrocytes.
It diminishes or suppresses disturbances due to hypoxia or deficient cerebral metabolism.
Capillary under the effects of Vinpocetine
The finished dosage form of Vinpocetine (Vinpocetine Covex 5 mg) is marketed as a prescription product in Azerbaijan, Armenia, Belarus, Bulgaria, Cuba, Georgia, Hungary, Kazakhstan, Latvia, Lithuania, Mongolia, Portugal, Czech Republic, Slovakia, Spain, Russia, Ukraine.
Restricted Area - Authorized Personnel Only
By accessing this website you accept and agree to the Data Protection and Legal Information. In order to comply with Spanish legislation on Advertising of Medicinal Products for Human Use, we must inform you that the information below is intended for health professionals.
By accessing this area a cookie is installed in your computer (or device), for more information on cookies please visit our cookie policy.
If you are not a healthcare professional, please refrain from accessing this website.